Hoth Therapeutics forms Rocket One space subsidiary

Hoth Therapeutics, Inc. formed a new wholly-owned subsidiary, Rocket One Inc., by filing Articles of Incorporation in Nevada on April 22, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Hoth Therapeutics, Inc. formed a new wholly-owned subsidiary, Rocket One Inc., by filing Articles of Incorporation in Nevada on April 22, 2026. Rocket One is intended to acquire, own and operate space-industry assets, including nano rocket systems used to deploy nanosatellites.

The company characterizes this as part of a potential expansion into the space industry and includes extensive cautionary language that these plans are forward-looking and subject to risks and uncertainties described in its prior SEC filings.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

wholly-owned subsidiary, nano rocket systems, forward-looking statements, Risk Factors

4 terms

wholly-owned subsidiary financial

"for the formation of its new wholly-owned subsidiary, Rocket One Inc."

A wholly-owned subsidiary is a company whose entire ownership is held by another company, called the parent, so the parent controls all shares, board appointments and major decisions. For investors this matters because the subsidiary’s profits, losses, assets and liabilities are treated as part of the parent’s financial picture, affecting valuation and risk exposure — imagine a parent owning a single storefront outright and consolidating its receipts and bills into the parent’s books.

nano rocket systems technical

"including nano rocket systems for the deployment of nanosatellites."

forward-looking statements regulatory

"includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Risk Factors regulatory

"the factors described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Hoth Therapeutics (HOTH) announce regarding Rocket One Inc.?

Hoth Therapeutics announced the formation of Rocket One Inc., a new wholly-owned Nevada subsidiary. Rocket One is intended to acquire, own and operate space-industry assets, including nano rocket systems for deploying nanosatellites, signaling an initial move toward space-related business activities.

What is the business focus of HOTH’s new subsidiary Rocket One Inc.?

Rocket One Inc. was formed to acquire, own and operate assets related to the space industry. This includes nano rocket systems designed for the deployment of nanosatellites, indicating a focus on small-scale launch and satellite deployment capabilities within the broader space sector.

When was Rocket One Inc. formed by Hoth Therapeutics (HOTH)?

Rocket One Inc. was formed on April 22, 2026, when Hoth Therapeutics filed Articles of Incorporation in Nevada. This filing officially established Rocket One as a wholly-owned subsidiary intended for space-industry activities and potential expansion into nanosatellite deployment technologies.

Is Hoth Therapeutics’ expansion into the space industry guaranteed to occur?

Hoth Therapeutics emphasizes that its potential expansion into the space industry is a forward-looking plan and inherently uncertain. The company notes that actual results may differ materially due to market conditions and risk factors described in its Annual Report and other SEC filings.

How does HOTH describe the risks around Rocket One and space-industry plans?

Hoth states that all forward-looking statements about Rocket One and space expansion are based on current expectations and assumptions. It warns that important factors, including market conditions and risks outlined under “Risk Factors” in its Form 10-K, could cause materially different outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/06/2026 - 04:07 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 22, 2026

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-38803		82-1553794
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

720 Monroe Street, Suite E514

Hoboken, NJ 07030

(Address of principal executive offices, including ZIP code)

(866) 239-7459

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		HOTH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 22, 2026, Hoth Therapeutics, Inc. (the “Company”) filed Articles of Incorporation with the Secretary of State of the State of Nevada for the formation of its new wholly-owned subsidiary, Rocket One Inc. (“Rocket One”). Rocket One was formed to acquire, own and operate assets related to the space industry, including nano rocket systems for the deployment of nanosatellites.

Cautionary Note Regarding Forward Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this Current Report on Form 8-K include, but are not limited to, statements that relate to the Company’s potential expansion into the space industry and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

- 1 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 6, 2026	Hoth Therapeutics, Inc.

	/s/ Robb Knie
	Robb Knie
	Chief Executive Officer

- 2 -

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents